Novo-backed Windward Bio targets $1bn valuation in US IPO

Swiss drug developer Windward Bio is targeting a valuation of up to $1bn in its US initial public offering, as a strong run for the biotech listings market extends into November.
The Basel-based company is seeking to raise up to $185.3mn by selling roughly 10.3mn shares priced between $16 and $18. It will list on the Nasdaq under the symbol (WWB).
Healthcare, seen as a defensive sector, has anchored this year’s autumn IPO window as choppy market conditions and rising borrowing costs weigh on activity elsewhere. Drug developer Rezera began its US roadshow last week and is expected to go public in New York this week.
Windward has raised $310mn in equity financing from Novo Holdings and other healthcare investors, including OrbiMed, Blue Owl and RTW Investments. The company is developing antibody medicines for serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease and atopic dermatitis.
Sanofi (SNY) has agreed to buy $50mn of shares and pre-funded warrants in a private placement. Jefferies, TD Cowen, Piper Sandler and UBS Investment Bank are underwriting the offering.


